Grippol Quadrivalent — Competitive Intelligence Brief

Grippol Quadrivalent (Grippol Quadrivalent) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated influenza vaccine Immunology / Infectious Disease Biologic

Target snapshot

Grippol Quadrivalent (Grippol Quadrivalent) — NPO Petrovax. Grippol Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Grippol Quadrivalent TARGET	Grippol Quadrivalent	NPO Petrovax	phase 3	Inactivated influenza vaccine
High-Dose Influenza Vaccine	High-Dose Influenza Vaccine	Saad Jamshed MD	marketed	Inactivated influenza vaccine
Trivalent sub-unit influenza vaccine	Trivalent sub-unit influenza vaccine	University of Witwatersrand, South Africa	marketed	inactivated influenza vaccine
Fluarix Tetra Vaccine	Fluarix Tetra Vaccine	GlaxoSmithKline	marketed	Inactivated influenza vaccine
inactivated split-virus influenza vaccine	inactivated split-virus influenza vaccine	The Cleveland Clinic	marketed	inactivated influenza vaccine
Vaxigrip®	Vaxigrip®	National University Hospital, Singapore	marketed	Inactivated influenza vaccine
Vaxigrip Tetra Sanofi Pasteur Europe	Vaxigrip Tetra Sanofi Pasteur Europe	Aarhus University Hospital	marketed	Inactivated influenza vaccine (quadrivalent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class